City Therapeutics (NASDAQ:CTY) Coverage Initiated by Analysts at Zacks Research

Zacks Research started coverage on shares of City Therapeutics (NASDAQ:CTY) in a research report report published on Wednesday,Zacks reports. The brokerage issued a hold rating on the stock.

CTY has been the topic of a number of other reports. Stifel Nicolaus started coverage on City Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $34.00 price target on the stock. Oppenheimer initiated coverage on City Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $46.00 price objective for the company. Jefferies Financial Group began coverage on City Therapeutics in a report on Tuesday. They issued a “buy” rating and a $32.00 target price on the stock. Finally, Wall Street Zen raised City Therapeutics to a “hold” rating in a research report on Saturday, October 24th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $37.33.

City Therapeutics Price Performance

Shares of CTY opened at $18.98 on Wednesday. City Therapeutics has a 1-year low of $15.81 and a 1-year high of $23.88.

Insider Buying and Selling

In other City Therapeutics news, Director Robert Nelsen purchased 170,000 shares of the firm’s stock in a transaction on Monday, October 19th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $3,060,000.00. Following the completion of the transaction, the director owned 13,692,507 shares of the company’s stock, valued at approximately $246,465,126. The trade was a 1.26% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Arch Venture Partners Xii, Llc purchased 170,000 shares of the company’s stock in a transaction dated Monday, October 19th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $3,060,000.00. Following the purchase, the insider directly owned 13,692,507 shares in the company, valued at approximately $246,465,126. The trade was a 1.26% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

About City Therapeutics

City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases. Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company’s activities center on building a therapeutic pipeline rather than marketing established products.